Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus sintilimab neoadjuvant therapy for locally advanced renal cell carcinoma (phase II, single arm)
ChiCTR2000039666Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and sintilimab in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Proportion of patients with >=40% reduction in tumor volume (including tumor thrombus and/or lymph nodes). Started Dec 2020; status: recruiting.
02
Drugs
axitinibsintilimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2000039666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039666.